Persons Evaluated for 2019 Novel Coronavirus — United States, January 2020

Bajema, Kristina L.; Oster, Alexandra M.; McGovern, Olivia L.; Lindstrom, Stephen; Stenger, Mark; Anderson, Tara; Isenhour, Cheryl; Clarke, Kevin R.; Evans, Mary; Chu, Victoria; Biggs, Holly M.; Kirking, Hannah L.; Gerber, Susan I.; Hall, Aron J.; Fry, Alicia M.; Oliver, Sara E.; Abedi, Glen R.; Bower, William A.; Chatham‐Stephens, Kevin; Conklin, Laura; Cooley, Laura A.; Cortese, Margaret M.; Curns, Aaron T.; Dooling, Kathleen; Gokhale, Runa; Gold, Jeremy A W; Grant, Gavin B.; Gutman, Julie; Hesse, Elisabeth; Kamili, Shifaq; Kim, Lindsay; Kirkcaldy, Robert D.; Koumans, Emily H.; Kujawski, Stephanie; Langley, Gayle; Lively, Joana Y; Lu, Xiaoyan; Lynch, Brian; Lyss, Sheryl; Malapati, Lakshmi; Martin, Michael; Mbaeyi, Sarah; McClung, Paul; Midgley, Claire M; Miller, Maureen; Morales, Michelle; Murray, Janna; Fiebelkorn, Amy Parker; Patel, Manisha; Peacock, Georgina; Pierce, Taran; Rha, Brian; Sakthivel, Senthilkumar K.; Schneider, Eileen; Siegel, David A.; Sunshine, Brittany; Wallace, Megan; Wang, Limin; Watson, John T.; Whitaker, Brett; Yousaf, Anna R

doi:10.15585/mmwr.mm6906e1

Cited by 168 publications

(148 citation statements)

References 3 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…The COVID-19 Investigation Team* Letters Nature MediciNe range 66-389 U l −1 ) at a median of illness day 14 (range: [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23]. Three of seven hospitalized patients had mildly elevated alkaline phosphatase levels >115 U l −1 (maximum value 163 U l −1 ).…”

Section: Clinical and Virologic Characteristics Of The First 12 Patiementioning

confidence: 99%

“…Left basilar opacity (9) Multifocal infiltrates, mediastinal and hilar lymphadenopathy c (7) Right lower lobe infiltrate (4) Patchy and linear opacities in the bilateral mid and lower lung fields (7) Bilateral mid and lower lung consolidations (12) Bilateral patchy lower lung opacities (10) Opacification of the left lower lung (7) T max , o F (d) 102.9 (7,9,11) 100.8 (10) 99.2 (4,5) 102.7 (9) 99.1 (9) 102.6 (10) 102.4 (9) Lowest SpO 2 , % (d) 90 (10,12) 93 (23,24) 88 (4) 87 (12) 93 (13,14) 86 (12) 92 (11) Maximum O 2 support received, l min −1 129 (13) 46 (19) 47 (11) 99 (7) 190 (13) 167 (12) 163 (14) Peak ALT, U l −1 (d) 219 (13) 66 (23) 75 (12) 136 (6) 389 (15) 248 (14) 127 (14) Lowest WBC count, cells per µl (d) 3,300 (9) 3,000 (8,12,19) 3,400 (4) 3,900 (5) 3,900 (13) 5,700 (15) 2,400 (10) Highest procalcitonin, ng ml −1…”

Section: Nature Medicinementioning

confidence: 99%

See 1 more Smart Citation

Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Team¹

2020

Nat Med

321

123

View full text Add to dashboard Cite

Data on the detailed clinical progression of COVID-19 in conjunction with epidemiological and virological characteristics are limited. In this case series, we describe the first 12 US patients confirmed to have COVID-19 from 20 January to 5 February 2020, including 4 patients described previously 1-3 . Respiratory, stool, serum and urine specimens were submitted for SARS-CoV-2 real-time reverse-transcription polymerase chain reaction (rRT-PCR) testing, viral culture and whole genome sequencing. Median age was 53 years (range: 21-68); 8 patients were male. Common symptoms at illness onset were cough (n = 8) and fever (n = 7). Patients had mild to moderately severe illness; seven were hospitalized and demonstrated clinical or laboratory signs of worsening during the second week of illness. No patients required mechanical ventilation and all recovered. All had SARS-CoV-2 RNA detected in respiratory specimens, typically for 2-3 weeks after illness onset. Lowest real-time PCR with reverse transcription cycle threshold values in the upper respiratory tract were often detected in the first week and SARS-CoV-2 was cultured from early respiratory specimens. These data provide insight into the natural history of SARS-CoV-2. Although infectiousness is unclear, highest viral RNA levels were identified in the first week of illness. Clinicians should anticipate that some patients may worsen in the second week of illness.Twelve patients with confirmed COVID-19 were identified in six states. Five did not require hospitalization and were isolated at home (patients 1-5) and seven were hospitalized for clinical and public health reasons (patients 6-12) ( Fig.

show abstract

Section: Clinical and Virologic Characteristics Of The First 12 Patiementioning

confidence: 99%

Section: Nature Medicinementioning

confidence: 99%

Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Team¹

2020

Nat Med

321

123

View full text Add to dashboard Cite

show abstract

“…European study reported to be present in 48% of the sample [10,13]. Cough or dyspnoea were reported by 82% of the patients in one study from Canada [9] and 90% in the USA [14].…”

Section: Symptomsmentioning

confidence: 91%

Identifying baseline clinical features of people with COVID-19

Ferreira-Santos

Maranhão

Monteiro‐Soares

2020

Preprint

View full text Add to dashboard Cite

Objectives: To describe baseline clinical characteristics of adult patients with COVID-19.Methods: We conducted a scoping review of the evidence available at LitCovid, until March 23th, 2020, and selected articles that reported the prevalence of socio-demographic characteristics, symptoms and co-morbidities in adults with COVID-19.Results: In total, 1 572 publications were published on LitCovid. We have included 56 articles in our analysis, with 89% conducted in China, and 75% contained inpatients. Three studies were conducted in North America and one in Europe. Participants' age ranged from 28 to 70 years, with balanced gender distribution. Proportion of asymptomatic cases were from 2 to 79%. The most common reported symptoms were fever [4-99%], cough [4-92%], dyspnoea/shortness of breath [1-90%], fatigue 4-89%], myalgia [3-65%], and pharyngalgia [2-61%], while regarding co-morbidities we found cardiovascular disease [1-40%], hypertension [0-40%] and cerebrovascular disease [1-40%]. Such heterogeneity impairs the conduction of meta-analysis. Conclusions:The infection by COVID-19 seems to affect people in a very diverse manner and with different characteristics. With the available data it is not possible to clearly identify those at higher risk of being infected with this condition. Furthermore, the evidence from countries other than China is, at the day, too scarce.

show abstract

“…Therefore, the current glucocorticoid treatment of 2019-nCoV-related pneumonia is still controversial. At present, it is only recommended to try intravenous methylprednisolone for 3-5 days, and it is not suitable for long-term use (42,43).…”

Section: Glucocorticoidmentioning

confidence: 99%

Research Progress of Drug Treatment in Novel Coronavirus Pneumonia

et al. 2020

View full text Add to dashboard Cite

As of March 10, 2020, more than 100,000 novel coronavirus pneumonia cases have been confirmed globally. With the continuous spread of the new coronavirus pneumonia epidemic in even the world, prevention and treatment of the disease have become urgent tasks. The drugs currently being developed are not adequate to deal with this critical situation. In addition to being controlled through effective isolation, we need a rapid response from the healthcare and biotechnology industries to accelerate drug treatment research. By reviewing the currently available literature published at home and abroad, we summarize the current research progress of drug treatment during the epidemic period. At present, the drugs that can be used for treatment mainly include antiviral drugs, antimalarials, glucocorticoids, plasma therapy, biological agents, and traditional Chinese medicine. The effectiveness and safety of drug therapy need to be confirmed by more clinical studies.

show abstract

Persons Evaluated for 2019 Novel Coronavirus — United States, January 2020

Cited by 168 publications

References 3 publications

Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Identifying baseline clinical features of people with COVID-19

Research Progress of Drug Treatment in Novel Coronavirus Pneumonia

Contact Info

Product

Resources

About